Sana Biotechnology, Inc.
NASDAQ:SANA
4.29 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 161.527 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 3.895 | 3.746 | 7.541 | 4.499 | 7.849 | 7.7 | 7.442 | 7.193 | 3.8 | 6.22 | 5.582 | 4.641 | 4.046 | 3.645 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -3.895 | -3.746 | -7.541 | -4.499 | -7.849 | -7.7 | -7.442 | -7.193 | -3.8 | -6.22 | -5.582 | -4.641 | -4.046 | -3.645 | 161.527 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 36.299 | 89.071 | 48.541 | -17.002 | 99.723 | 67.286 | 58.467 | 70.673 | 54.612 | 17.251 | 98.6 | 69.998 | -31.029 | 168.93 | 104.117 | 44.545 | 81.897 | 27.32 | 39.274 |
| General & Administrative Expenses
| 16.442 | 16.269 | 20.784 | 19.183 | 16.566 | 16.766 | 23.321 | 15.514 | 18.292 | 14.434 | 12.679 | 13.433 | 12.477 | 11.821 | 9.207 | 7.099 | 6.009 | 5.955 | 5.818 |
| Selling & Marketing Expenses
| -3.895 | -3.746 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.547 | 12.523 | 20.784 | 19.183 | 16.566 | 16.766 | 23.321 | 15.514 | 18.292 | 14.434 | 12.679 | 13.433 | 12.477 | 11.821 | 9.207 | 7.099 | 6.009 | 5.955 | 5.818 |
| Other Expenses
| -4.121 | 0.215 | -0.224 | 0.303 | -0.084 | -0.047 | -0.268 | -0.106 | -0.198 | -0.102 | 0.281 | 0.01 | 0.001 | 0.013 | 0.029 | 0.044 | 0.019 | 0.005 | 0.023 |
| Operating Expenses
| 48.846 | 101.594 | 69.325 | 2.181 | 116.289 | 84.052 | 81.788 | 86.187 | 72.904 | 31.685 | 111.279 | 83.431 | -18.552 | 180.751 | 113.324 | 51.644 | 87.906 | 33.275 | 45.092 |
| Operating Income
| -52.741 | -105.34 | -76.866 | -2.181 | -116.289 | -84.052 | -81.788 | -86.187 | -72.904 | -31.685 | -111.279 | -83.431 | 18.552 | -180.751 | -113.324 | -51.644 | -87.906 | -33.275 | -45.092 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.702 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.45 | -2.135 | -11.251 | 0.303 | -0.084 | 1.929 | 1.345 | 1.067 | 0.439 | 0.237 | 0.281 | 0.01 | 0.001 | 0.013 | 0.029 | 0.044 | 0.019 | 0.005 | 0.023 |
| Income Before Tax
| -50.291 | -107.475 | -88.117 | 0.984 | -113.999 | -82.123 | -80.443 | -85.12 | -72.465 | -31.448 | -110.731 | -83.263 | 18.683 | -180.617 | -113.17 | -51.452 | -87.808 | -32.875 | -44.388 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.701 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 3.703 | 7.497 | -2.862 | -6.822 | -1.929 | -2.021 | -1.173 | -0.637 | -0.237 | -3.602 | -0.158 | -0.13 | -0.121 | -1.88 | -0.148 | -0.079 | -0.395 | -1.343 |
| Net Income
| -50.291 | -107.475 | -88.117 | 0.984 | -113.999 | -80.194 | -78.422 | -83.947 | -71.828 | -31.211 | -110.731 | -83.263 | 18.683 | -180.617 | -113.17 | -51.452 | -87.808 | -32.875 | -43.045 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.701 | 0 | 0 | 0 | 0 |
| EPS
| -0.21 | -0.49 | -0.45 | 0.005 | -0.59 | -0.42 | -0.41 | -0.44 | -0.38 | -0.17 | -0.6 | -0.46 | 0.1 | -1.52 | -0.65 | -0.39 | -0.67 | -0.25 | -0.33 |
| EPS Diluted
| -0.21 | -0.49 | -0.45 | 0.005 | -0.59 | -0.42 | -0.41 | -0.44 | -0.38 | -0.17 | -0.6 | -0.46 | 0.09 | -1.52 | -0.65 | -0.39 | -0.67 | -0.25 | -0.33 |
| EBITDA
| -48.846 | -101.594 | -69.325 | 2.318 | -116.289 | -84.052 | -81.788 | -82.171 | -69.104 | -28.071 | -111.279 | -80.549 | 21.158 | -178.504 | -113.324 | -50.124 | -86.525 | -32.01 | -44.064 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.702 | 0 | 0 | 0 | 0 |